PRTK
$4.51
Paratek Pharma
$.10
2.27%
PRTK
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.14)
Revenue:  $45.21 Mil
Monday
Aug 10
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PRTK reports earnings?
Beat
Meet
Miss

Where is PRTK's stock price going from here?
Up
Flat
Down
Stock chart of PRTK
Analysts
Summary of analysts' recommendations for PRTK
Score
Grade
Pivots
Resistance
$4.81
$4.68
$4.60

$4.47

Support
$4.39
$4.26
$4.18
Tweet
Growth
Description
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.